View More Recent Stories

Jun 17, 2025 04:27AM UBS Upgrades Alkermes (ALKS) to Buy
Jun 10, 2025 09:48AM RBC Capital on Alkermes (ALKS): 'Can Orexins Go Wrong? 5 Key Things We Are Watching For'
May 14, 2025 09:36AM Stifel Reiterates Buy Rating on Alkermes (ALKS)
May 12, 2025 07:04AM Cantor Fitzgerald Reiterates Overweight Rating on Alkermes (ALKS)
May 1, 2025 10:34AM Stifel Reiterates Buy Rating on Alkermes (ALKS), 'We Remain Bullish Into NT1 (Early-3Q) & NT2 ("Fall") Ph2 Data'
May 1, 2025 07:03AM Alkermes (ALKS) Misses Q1 EPS by 18c
Apr 22, 2025 09:33AM TD Cowen Reiterates Buy Rating on Alkermes (ALKS)
Apr 16, 2025 07:58AM Alkermes (ALKS) announces passing of Chief Financial Officer
Mar 13, 2025 06:58AM Cantor Biotech industry report, buying value in RevGens
Mar 13, 2025 05:32AM RBC Capital Starts Alkermes (ALKS) at Sector Perform
Feb 13, 2025 11:44AM Alkermes (ALKS) PT Raised to $32 at Goldman Sachs
Feb 13, 2025 09:28AM Cantor Fitzgerald Reiterates Overweight Rating on Alkermes (ALKS)
Feb 12, 2025 01:18PM Jefferies Reiterates Buy Rating on Alkermes (ALKS)
Feb 12, 2025 07:01AM Alkermes (ALKS) Tops Q4 EPS by 30c
Feb 11, 2025 04:14AM Deutsche Bank Starts Alkermes (ALKS) at Buy
Jan 29, 2025 09:12AM Cantor Fitzgerald provides update on Biotechnology stocks
Jan 27, 2025 11:34AM Jefferies on Alkermes (ALKS): 'We continue to think '2680 has a clean safety profile'
Jan 6, 2025 10:35AM TD Cowen: '10 Potential "Thome Run" Catalysts to Watch in 2025'
Jan 2, 2025 01:02PM Piper Sandler Highlights NBIX, ITCI, ALKS, AXSM as High Conviction Ideas in Biotechnology
Dec 11, 2024 07:35AM Piper Sandler Provides 'Expert Perspectives On Orexin Agonists And An Evolving Sleep/Wake Space'
Dec 5, 2024 07:30AM Piper Sandler Reiterates Overweight Rating on Alkermes (ALKS)
Nov 13, 2024 08:10AM Alkermes (ALKS) PT Raised to $40 at Mizuho
Nov 4, 2024 04:23PM Stifel Upgrades Alkermes (ALKS) to Buy
Oct 28, 2024 07:28AM H.C. Wainwright Reiterates Neutral Rating on Alkermes (ALKS)
Oct 25, 2024 09:07AM Alkermes (ALKS) PT Lowered to $37 at Piper Sandler
Oct 25, 2024 05:43AM Alkermes (ALKS) PT Lowered to $30 at Goldman Sachs
Oct 25, 2024 05:39AM Leerink Partners Reiterates Market Perform Rating on Alkermes (ALKS)
Oct 24, 2024 10:56AM Alkermes (ALKS) PT Lowered to $25 at Stifel
Oct 24, 2024 07:02AM Alkermes (ALKS) Tops Q3 EPS by 1c
Oct 14, 2024 06:58AM H.C. Wainwright Reiterates Neutral Rating on Alkermes (ALKS)
Oct 10, 2024 08:24AM TD Cowen Reiterates Buy Rating on Alkermes (ALKS)
Oct 10, 2024 07:22AM Piper Sandler Reiterates Overweight Rating on Alkermes (ALKS)
Oct 10, 2024 06:48AM Baird Reiterates Outperform Rating on Alkermes (ALKS)
Oct 10, 2024 05:42AM JPMorgan Reiterates Neutral Rating on Alkermes (ALKS)
Oct 1, 2024 07:11AM Mizuho Reiterates Outperform Rating on Alkermes (ALKS)
Oct 1, 2024 06:16AM Mizuho Reiterates Outperform Rating on Alkermes (ALKS)
Sep 26, 2024 07:07AM Piper Sandler Reiterates Overweight Rating on Alkermes (ALKS)
Sep 26, 2024 06:37AM Mizuho Reiterates Outperform Rating on Alkermes (ALKS)
Sep 26, 2024 05:39AM Mizuho Reiterates Outperform Rating on Alkermes (ALKS)
Sep 23, 2024 12:10PM Alkermes (ALKS) Shares Trade off LOD, Down ~2%, Jefferies Out With Cmnts from Mgmt Meet
Sep 10, 2024 01:15PM Mizuho on Alkermes (ALKS): 'we believe these data are not sufficient to draw any definitive conclusion'
Aug 22, 2024 07:02AM Alkermes (ALKS) Announces Initiation of Vibrance-2 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Narcolepsy Type 2
Jul 25, 2024 06:55AM Alkermes (ALKS) PT Raised to $38 at Baird
Jul 25, 2024 06:50AM Alkermes (ALKS) PT Raised to $37 at H.C. Wainwright
Jul 24, 2024 07:01AM Alkermes (ALKS) Tops Q2 EPS by 4c
Jun 17, 2024 05:29AM TD Cowen Starts Alkermes (ALKS) at Buy
View More Recent Stories